Arjun Goyal - Jun 2, 2021 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Director
Signature
/s/ Marella Thorell, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Jun 2, 2021
Transactions value $
$49,999,998
Form type
4
Date filed
6/4/2021, 05:00 PM
Previous filing
May 27, 2021
Next filing
Jul 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Conversion of derivative security +3.1M 3.1M Jun 2, 2021 See footnote F1, F2, F3
transaction CNTA Ordinary Shares Conversion of derivative security +85.9K 85.9K Jun 2, 2021 See footnote F1, F2, F4
transaction CNTA Ordinary Shares Purchase $14.6M +730K +23.57% $20.00 3.83M Jun 2, 2021 See footnote F1, F3
transaction CNTA Ordinary Shares Purchase $405K +20.3K +23.57% $20.00 106K Jun 2, 2021 See footnote F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTA Series A Preferred Shares Award $34.1M +3.1M $11.00 3.1M Jan 29, 2021 Ordinary Shares 3.1M See footnote F1, F2, F3, F5, F6
transaction CNTA Series A Preferred Shares Award $945K +85.9K $11.00 85.9K Jan 29, 2021 Ordinary Shares 85.9K See footnote F1, F2, F4, F5, F6
transaction CNTA Series A Preferred Shares Conversion of derivative security $0 -3.1M -100% $0.00* 0 Jun 2, 2021 Ordinary Shares 3.1M See footnote F1, F2, F3
transaction CNTA Series A Preferred Shares Conversion of derivative security $0 -85.9K -100% $0.00* 0 Jun 2, 2021 Ordinary Shares 85.9K See footnote F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Immediately prior to the closing of the initial public offering, the Series A Preferred Shares automatically converted on a one-to-one basis into Ordinary Shares without payment or further consideration. The Series A Preferred Shares had no expiration date.
F3 Held by Vida Ventures II, LLC ("Vida II Main Fund"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II Main Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4 Held by Vida Ventures II-A, LLC ("Vida II Parallel Fund"). VV Manager II is the manager of Vida II Parallel Fund. The Reporting Person is a member of the investment committee of VV Manager II. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F5 This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
F6 On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split.